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Available online 28 August 2019Background: Despite great efforts to identify druggable molecular targets for AML, there remains an unmet need
for more effective therapies.
Methods:An in silico screeningwas performed using ConnectivityMaps to identify FDA-approved drugs thatmay
revert an early leukaemic transformation gene signature. Hit compounds were validated in AML cell lines. Cyto-
toxic effects were assessed both in primary AML patient samples and healthy donor blood cells. Xenotransplan-
tation assays were undertaken to determine the effect on engraftment of hit compounds. The mechanism of
action responsible for the antileukaemic effect was studied focussing on lysosomes and mitochondria.
Findings:We identified a group of antihistamines (termed ANHAs) with distinct physicochemical properties as-
sociated with their cationic-amphiphilic nature, that selectively killed leukaemic cells. ANHAs behaved as
antileukaemic agents against primary AML samples ex vivo, sparing healthy cells. Moreover, ANHAs severely im-
paired the in vivo leukaemia regeneration capacity. ANHAs' cytotoxicity relied on simultaneous mitochondrial
and lysosomal disruption and induction of autophagy and apoptosis. The pharmacological effect was exerted
based on their physicochemical properties that permitted the passive targeting of both organelles, without the
involvement of active molecular recognition.
Interpretation: Dual targeting of lysosomes and mitochondria constitutes a new promising therapeutic approach
for leukaemia treatment, supporting the further clinical development.
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Acute myeloid leukaemia (AML) is a clinically and biologically het-
erogeneous disease characterized by the accumulation of immature
transformed myeloid progenitors in bone marrow (BM). Although sig-
nificant research efforts have been invested in improving outcomes
for AML patients, the standard therapy formost subtypes of newly diag-
nosedAMLhas remained practically unchanged over the past 4 decades,
and the prognosis is still poor [1]. Indeed, most patients with AML will
relapse after achieving complete remission,with treatment of refractory
and relapsed AMLbeing challenging in clinics. Therefore, new therapeu-
tic approaches with high specificity and effectiveness are urgently
needed.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Despite great efforts to identify druggable molecular targets for
acute myeloid leukaemia, there remains an unmet need for more
effective therapies. In this quest, in silico identification of
repurposing drug candidates has been proven useful in the search
for potential therapies. As such, several antihistamines have been
preclinically described as antineoplastic agents in non-AML
tumors.
Added value of this study
In our study, we described the antileukaemic potential of several
antihistamines and demonstrated its histamine receptor-
independence. Rather than a specificmolecular target recognition,
the mechanism of action was found to rely on the simultaneous
disruption of lysosomes and mitochondria, based on the physico-
chemical properties of these drugs.
Implications of all the available evidence
The preclinical results presented in the study are in line with previ-
ous results in lung cancer and constitute a stepping stone towards
the development of novel treatments for AML independent of ac-
tive molecular recognition and based on simultaneous lysosomal
and mitochondrial functionality disruption.
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through disease progression and/or relapse, affecting both the geno-
type and the phenotype of leukaemic subclones [2–6]. Cytogeneti-
cally, 50% of AML patients present normal karyotypes, suggesting
the existence of other molecular events in leukaemogenesis [7]. De-
spite this disease complexity, MLL fusion genes have been demon-
strated capable of initiating human leukaemogenesis in vivo, as
their expression is sufficient to transform human haematopoietic
progenitors and mature cells into leukaemic cells [8–10]. Specifi-
cally, MLL-AF9 fusion protein does not require collaborating muta-
tions to induce leukaemia transformation [11]. Although MLL-AF9
rearrangement is rarely found in AML patients (below 1%) [12,13],
MLL-AF9 AML model faithfully recapitulates key aspects for this dis-
ease, including in vivo regeneration capacity, clonogenicity and phe-
notype [8,9].
Although the hypothesis that histamine might be involved in carci-
nogenesis was proposed several decades ago [14], it remains under dis-
cussion today. Indeed, the evidence linking antihistamines per se to
cancer is controversial and complex [15,16]. In the Haematology field,
the antileukaemia effect of terfenadine has been recently described,
suggesting a non-canonical mechanism of action [17]. Similar results
were obtained in other solid tumors when different antihistamines
were studied for their antineoplastic activity [18–24], mainly through
an HRH1-independent mechanism.
Based on the gene expression profile associated with MLL-AF9-
driven early transformation events in AML, a group of antihista-
mines was identified as potent antileukaemic agents due to their
histamine receptor-independent physicochemical properties allowing
mitochondrial and lysosomal disruption. Simultaneously targeting
both organelles constitutes a new therapeutic approach for haema-
tological neoplasias, affecting both the bulk population and the
most primitive cell fraction without significant effect on their
healthy counterparts.2. Materials and methods
2.1. AML cell lines and cell cultures
Cell lines HL-60 (ACC-3), KG-1 (ACC-14), MonoMac-1 (ACC-252) K-
562 (ACC-10), Jurkat (ACC-282), RPMI-8402 (ACC-290), CCRF-CEM
(ACC-240), RAMOS (ACC-603), GRANTA-519 (ACC-342), RPMI-8226
(ACC-402), JJN-3 (ACC-541) and U-266 (ACC-9) were obtained from
DSMZ (Braunschweig, Germany). THP-1 cell line (TIB-202™) was ob-
tained from ATCC (Manassas, VA, USA). HBL-2 cell line was kindly sup-
plied by Dr. Pérez-Galán.
2.2. Primary samples
Primary AML samples were obtained from patients diagnosed at
Hospital Clínic of Barcelona (Spain) and Hospital Germans Trias i Pujol
(Badalona, Spain). AML diagnosis and classificationwere based on stan-
dardWHO criteria (70). Main AML patient's characteristics are summa-
rized in Table S1. Mononuclear cells (MNCs) were isolated by Ficoll
density gradient centrifugation (GE, Chicago, IL, USA). All patients pro-
vided written informed consent in accordance with the Declaration of
Helsinki, and the studywas approved by the corresponding Ethics Com-
mittees. Blood mature MNCs were isolated from healthy-donor buffy
coats provided by Banc de Sang i Teixits (BSiT, Barcelona, Spain). Umbil-
ical cord blood was provided by BSiT, andMNCs were depleted for line-
age marker-positive cells using magnetic separation with human
Lineage Cell Depletion kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) following manufacturer's recommendations.
2.3. Drugs and antibodies
All drugs were resuspended in H2O (Thermo Fischer Scientific, Wal-
tham, MA, USA), DMSO (Sigma-Aldrich, St. Louis, MO, USA) or ethanol
(VWR) according to manufacturer's specifications. Antibodies used in
this study are summarized in Table S3.
2.4. Cytotoxicity assays
2 × 105 (72 h assays), 3 × 105 (48 h assays) or 7.5 × 105 (primary
AML) cells per mL were cultured in 96-well plates and all drugs were
added at the indicated concentrations. In co-culture experiments, 2
× 105 CFSE-stained HS-5 cells per mL were seeded in 96-well plates.
AML cell lines at 2 × 105 cells per mL were subsequently added. In Z-
VAD-FMK experiments cells were pretreated 20 min with Z-VAD-FMK
50 μM. In α-tocopherol experiments, cells were pretreated for 24 h
with growing concentrations of α-tocopherol and later incubated with
antihistamines for 48 h. Cell viability was measured by 7-AAD
(eBioscience, San Diego, CA, USA) exclusion and Hoechst33342
(Sigma-Aldrich) positivity staining by flow cytometry, and cell count
was obtained by volume. In experiments with primary cells, analyses
were performed inside the blast population as detected by blast gates
(CD45low SSCint).
2.5. Proliferation assay
HL-60 and KG-1 cells were stained with 2,5 μM CFSE (CellTrace™
CFSE Cell Proliferation kit, Thermo Fisher). Drugs were added at the in-
dicated concentrations.
2.6. Clonogenicity assay
1 × 103 cells of AML cell lines or 50 × 103 primary AML cells or lin-
depleted UCB cells were treated at the indicated concentration for
18 h and cultured in 1 mL of MethoCult H4034 Optimum (StemCell
Technologies, Vancouver, BC, Canada). Colonies were screened based
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cells and lineage-depleted UCB cells).
2.7. In vivo studies
6–8week-oldNOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG, Jackson Lab-
oratories) mice were myeloablated with busulfan (30 mg/kg IP) at day
0. CD3-depleted primary AML patient samples or lineage-depleted
UCB cells were ex vivo treated in the indicated conditions, and 4–34
× 106 (AML) or 12–14 × 104 (lin− UCB) cells were injected IV and left
8–10 weeks untreated. Engraftment was determined as the percentage
of live human CD45-expressing cells in bone marrow as assessed by
flow cytometry. Mice were randomized and blind-coded at the begin-
ning of the experiment.
2.8. HRH1 immunofluorescence
A total of 3 × 105 cells were attached to poly-L-lysine (50 μg/mL)-
coated coverslips and fixed with formaldehyde 4% (Sigma), blocked
with γ-globulin (10 μg/mL) and stained with Hoechst33342 and HRH1
antibody (Antibodies-online GmbH, Aachen, Germany). Samples were
observed in a Leica DMI6000 B fluorescencemicroscope (Leica,Wetzlar,
Germany) and the images were analysed with Image J.
2.9. Lysotracker
4 × 105 cells per mL were treated, washed in HBSS and incubated
with 50 nM Lysotracker DeepRed (Thermo Fisher) and Hoechst33342
for 30 min at 37 °C. Cells were washed twice with HBSS and acquired
in a flow cytometer. For the microscopic analysis, 2 × 105 cells per con-
dition were treated, washed with complete medium and incubated 1 h
with 100 nM LysoTracker DeepRed and Hoechst 33342 at 37 °C. Cells
were attached to chambered coverslips (μ-Slide 8well, Ibidi) previously
treated with Poly-L-Lysine 50 μg/mL. Live cell images were acquired
with a Zeiss LSM880 confocal microscope (Zeiss, Jena, Germany).
2.10. Lysosomal membrane permeabilization
3 × 105 cells previously treated for 18 or 48 h with selected drugs
were attached to poly-L-lysine (50 μg/mL)-coated coverslips, fixed
with formaldehyde 4% (cathepsin B) or cold methanol (galectin-1)
and permeabilized with Triton X100 0.2%. Cells were then blocked
with γ-globulin (10 μg/mL) and incubated with cathepsin B
(NBP1–86048, 1:100) or galectin-1 (ab25138, 1:1000) antibodies.
Cells were subsequently incubated with Hoechst33342 and Alexa
Fluor 488 Goat Anti-Rabbit IgG. Images were acquired in a confocal mi-
croscope Zeiss LSM880 and analysed with Fiji software [25].
2.11. Cyto-ID staining
4× 105 cells permLwere treated for 18 hwith drugs at the indicated
concentrations, washed in PBS and incubated 30 min at 37 °C in PBS
with 5% FBS containing Hoechst 33342, 7-AAD and Cyto-ID green fluo-
rescent dye (CYTO-ID ® Autophagy detection kit, Enzo Life Sciences,
Farmingdale, NY, USA) at a 1:4000 dilution. Cells were washed with
PBS and acquired in a flow cytometer.
2.12. LC3B immunoblotting
10 × 106 AML cell lines or 25–50 × 106 primary AML cells per condi-
tion were treated in indicated conditions and subsequently harvested
and lysed in RIPA lysis buffer. Antibodies used for this technique are
listed on supplementary table 2. Imageswere acquired in a LICOROdys-
sey Imager and quantified using Fiji software.2.13. Mitochondrial reactive oxygen species (ROS)
4 × 105 cells/ml were treated at the indicated concentration of drugs
for 6 h and subsequently incubated with mitochondrial ROS detector
MitoSOX Red Mitochondrial Superoxide Indicator (Thermo Fischer Scien-
tific) 5 μM and Hoechst33342 for 10 min at 37 °C. Cells were washed
twice with HBSS and acquired in a FACSCantoII cytometer.
2.14. Rhodamine 123 assay
Changes in mitochondrial membrane potential were assessed using
the rhodamine 123 dye. Briefly, cells were treated for 18 h,washedwith
PBS and incubated with rhodamine-123 50 nM (15 min, 37 °C). Cells
were then washed twice with PBS and acquired in a flow cytometer.
2.15. CaspaseGlo assay
4 × 105 cells per mLwere seeded in 96-well plates and treated in in-
dicated conditions (50 μL final volume). 50 μL reconstituted
CaspaseGlo® 3/7 Assay substrate (Promega) were added, and the mix
was incubated 30′ at room temperature. Luminescence was analysed
using a Synergy HTMulti-DetectionMicroplate Reader (BioTek,Winoo-
ski, VT, USA) following manufacturer's recommendations.
2.16. Annexin V staining
3 × 105 cells permLwere treated for 48 hwith compounds at the in-
dicated concentrations. Annexin V membrane translocation was mea-
sured using the Annexin V apoptosis detection kit (Becton Dickinson,
Franklin Lakes, NJ, USA) according to the manufacturer's instructions.
Data were collected by flow cytometry
2.17. Flow cytometry
All flow cytometric experiments were performed with a FACSCanto
II cytometer (Becton Dickinson). All flow cytometric analysis was done
using FlowJo software (TriStar, Scottsdale, AZ, USA).
2.18. Statistics
Statistical significance was determined using GraphPad Prism® 6.01
(GraphPad software, La Jolla, CA, USA) by using the statistical tests spec-
ified in figure legends. Error bars correspond to SEM. All experiments
were done at least 2 times in biological triplicates, unless otherwise
specified in the figure legend.
2.19. Ethics approval
All patients provided written informed consent in accordance with
the Declaration of Helsinki, and the study was approved by the corre-
sponding Ethics Committees (Ethics Committee Hospital Clínic de
Barcelona, Ethics Committee Hospital Germans Trias i Pujol). All exper-
iments involvingmicewere approved by the Catalan Ethical Committee
of Animal Experimentation (CCEEA).
2.20. Availability of data and materials
The datasets used and/or analysed during the current study are
available from the corresponding author on reasonable request.
3. Results
3.1. A group of antihistamines displayed antileukaemic effects
To search for drugs that may revert early leukaemogenesis-related
events, the MLL-AF9-induced AML model was chosen, as MLL-AF9 not
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but also induces the aberrant expression of stem-cell genes that charac-
terize leukaemic stem cells capable of initiating, maintaining and prop-
agating the leukaemia [26]. The gene expression profile induced upon
MLL-AF9 expression in CD34+ cord blood cells [27] was screened in
the Connectivity Map database [28] in order to search for small bioac-
tive molecules that may revert the transformation-associated gene sig-
nature. Unexpectedly, four antihistamines were found among hit
compounds (Fig. S1). A primary screening on AML cell lines was per-
formed to validate the results obtained from the in silico prediction.
AML cell viability remained unaffected in the presence of histamine
(natural HR agonist), and HR type 2 (HRH2), HR type 3 (HRH3) and
HR type 4 (HRH4) antagonists. However, a subgroup of HRH1 inverse
agonists (loratadine, rupatadine, terfenadine and ebastine) (ANHA: An-
tiNeoplastic HRH1 inverse Agonist) significantly decreased leukaemic
survival (Fig. 1A and S2A; Table S4). Indeed, the antileukaemic effect
measured by the EC50 on AML cell lines was in the low micromolar
range (Fig. 1B and S2B), being similar in MLL-AF9-positive (MonoMac-
1, THP-1) and in MLL-AF9-negative (HL-60, KG-1) cell lines (Fig. S3).
At that concentration, ANHAs significantly reduced the proliferation
rate of AML cells (Fig. 1C and S2C). Moreover, the AML clonogenic ca-
pacity as measured by the colony-formation potential decreased in the
presence of ANHAs (Fig. 1D). As the block in differentiation is a hallmark
of AML, we interrogated the differentiation status of AML cells treated
with ANHAs. Upregulation of both CD11b and CD14 differentiation-
associated granulocyte and monocyte surface markers was detected
upon treatment (Fig. 1E and S2D). In concordance, treatment with
ANHAs lead to a G2/M cell-cycle arrest (Fig. 1F and S2E). Moreover,
ANHA treatment synergized with cytarabine, the backbone of chemo-
therapy regimen in AML (Fig. 1G), enabling the eradication of
cytarabine-resistant cells. Due to the well-described BMmicroenviron-
ment protection on AML [29], the antineoplastic effect of ANHA-drug
treatmentwas interrogated in amore relevant in vitro co-culture system
with HS-5 human BM stroma cells. Treatment of AML cells in direct con-
tact with HS-5 stromal monolayers did not overcome the cytotoxic ef-
fect of ANHAs (Fig. 1H and S2F). Our results suggest that ANHA
induced cytotoxicity on AML cells by promoting differentiation and
G2/M accumulation, and this neoplastic effect is stroma-independent.
The antileukaemic effect of ANHA was then evaluated ex vivo in 16
primary AML patient samples. The reduction of cell viability upon treat-
ment in all AML samples tested was dose- and time-dependent
(Fig. 2A). In contrast to AML cell lines (Fig. 1) where a 50% cell death
was achieved in the presence of 5–10 μM of each drug at 48 h post-
treatment, primary AML samples were more resistant, and a clinically
significant cytotoxic effect was detected at day 6. Interestingly, all the
AML samples tested were sensitive to the treatment. In order to mea-
sure the proliferation and differentiation ability of individual AML cells
and, therefore, their ex vivo stem-cell properties, the clonogenic capacity
was measured 18 h after treatment. Additionally, the total number of
colonies decreased to approximately 50% (Fig. 2B), suggesting that
ANHAs affected the most primitive fraction of AML cells.
As ANHAs are already FDA- and/or EMA-approved antihistamines,
the therapeutic maximal concentration achieved in plasma is already
known and ranges between 1 and 200 nM [30]. However, the cytotoxic
effect observed on AML cells was achieved at a low microMolar range;
therefore, the safety of these treatments on healthy blood cells was
tested at the same conditions as previously described for primary AML
samples. The cell viability of each blood-cell subtype (T, B and myeloid
cells) remained largely unaffected upon treatment; only the myeloid
population was significantly reduced in the presence of rupatadine
and ebastine at day 6 (Fig. 2C). Remarkably, treatment with ANHAs
spared the clonogenic capacity of healthy haematopoietic progenitor/
stem cells as shown in Fig. 2D, where no differences were observed in
the total number or relative frequency of each type of CFUs.
Only terfenadine significantly reduced the total number of CFUs and,
also considering its withdrawal from the market due to potentialcardiotoxicity, its study as a candidate was discontinued [31]. The
ratio between viability reduction and total CFUs generated fromhealthy
blood cells versus AML cells was calculated to reveal the higher selectiv-
ity of ANHAs for targeting AML (Fig. 2E).
3.2. ANHA treatment selectively impaired the leukaemia regeneration ca-
pacity in vivo
Next, the effect of ANHAs on the in vivo engraftment potential was
evaluated. Primary AML samples were treated ex vivo for 18 h and
transplanted into adult conditioned immunocompromised NSG mice.
Transplanted mice were left untreated for 8–10 weeks in order to mea-
sure the leukaemia regeneration capacity of AML cells upon treatment.
As shown in Fig. 3A, ebastine severely reduced the leukaemia burden
in BM, diminishing the presence of human AML cells in BM by N90%. In-
deed, 75% ebastine-treated mice displayed b3% AML blasts in BM as
compared to vehicle-treated control. The treatment with rupatadine
also induced a reduction of the engraftment capacity of AML cells in
N50%. However, no significant differences were detected in the leukae-
mia regeneration capacity upon loratadine treatment. As healthy con-
trol, lineage-depleted umbilical cord blood cells (lin− UCB cells) were
treated similarly to AML cells and transplanted into NSG mice. In con-
cordance with the lack of cytotoxic effect in healthy blood cells demon-
strated in Fig. 2, lin− UCB cells ex vivo treated with ebastine displayed a
slight reduction in normal haematopoietic potential as measured by the
human regeneration capacity on BM (Fig. 3B). Indeed, the frequency of
the most primitive haematopoietic human cell fraction represented by
CD34+ cells in BM was equivalent in all treated animals as compared
to vehicle-treated mice (Fig. 3C). Similar results were obtained in the
CD13+ myeloid and CD19+ lymphoid cell population (Fig. 3C). Again,
the ratio between the engraftment reduction levels observed in AML
vs. healthy blood cells revealed the high specificity towards neoplastic
cells (Fig. 3D). Thus, treatment with ANHAs dramatically reduced the
regeneration potential of AML cells with little effect on normal HSCs.
3.3. ANHA antineoplastic effect was not mediated by HRH1
Since ANHAs are well-known antihistamines that specifically recog-
nize HRH1, the role of this membrane receptor in leukaemogenesis was
studied. First, the cell-surface expression of HRH1 was evaluated on
AML cell lines. HRH1s were uniformly expressed on all AML cells
(Fig. 4A and B). However, the cytotoxic effect observed upon treatment
of AML cells with ANHAswas not reverted in the presence of the natural
ligand of HRH1, histamine (Figs. 4C and S4A), and no relationship was
found between the sensitivity of AML cells and the affinity of antihista-
mines for HRH1 asmeasured by the pKi value (Fig. 4D). To further study
the relationship between the antileukemic potential and HRH1, we
analysed both HRH1 expression and ANHA cytotoxicity in a broader
panel of leukemic cell lines. Although all the different leukaemic cell
lines tested were sensitive to ANHA treatment, HRH1 expression and
cytotoxicitywere inconsistent (Figs. 4E-G and Figs. S4B and S4C); equiv-
alent sensitivity to ANHA treatment was found in leukaemic cells with
dramatically different levels of HRH1 (0–100%). These results suggested
that ANHAs exerted their effect in a HRH1-independent manner; thus,
alternative already described targets were explored. Although many
HRH1 antagonists also inhibit muscarinic acetylcholine receptors
(mAChR) [32–34], no effect on cell viability was detected upon treat-
mentwithmAChR antagonists (Fig. S5A) neither acetylcholine reverted
the cytotoxicity induced by ANHAs (Fig. S5B). Next, we investigated the
role of the potassium voltage-gated channel subfamily H member 2
(hERG, KCHNH2 or Kv11.1) as many antihistamines block this channel
[35–37]. Yet, the survival of AML cells remained largely unaffected in
the presence of hERG blockers (Fig. S5C). Therefore, the pharmacologi-
cal effect of ANHAs on AML cells was not exerted by HRH1 inhibition,
mAChR modulation or hERG blockage.
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Cationic amphiphilic drugs (CADs) are molecules with a hydropho-
bic ring structure and a side chain with a cationic amine group [38]. As
CADs are not ionized at a physiologic pH and have overall hydrophobic-
ity, they can easily permeate through the plasma membrane [39].
Within the highly acidic lysosomal compartment, the amine is proton-
ated, and the drug is then trapped and concentrated, inducing mem-
brane structure perturbation and compromising cell viability [40,41].
Their uptake is therefore controlled by two major mechanisms: non-
specific binding to membrane phospholipids and ion-trapping within
acidic cellular compartment [18]. As ANHAs have been described as
CADs exerting cytotoxicity effects in solid tumors through lysosomal ac-
cumulation [18], the lysosome compartment was examined using the
acidotropic probe LysoTracker. As expected for CADs, AML cells treated
with ANHAs showed an enlargement of the lysosomemass, as detected
by fluorescence microscopy (Fig. 5A and S6A) and flow cytometry
(Fig. 5B and S6B); which constitutes a common event preceding the
cell death-inducer lysosomal membrane permeabilization (LMP) [42].
This phenomenon was detected by the formation of a punctate pattern
of Galectin 1 (LGALS1) (Fig. 5C and S6C), as a result of its translocation
from the cytosol to damaged lysosomes. As a consequence of LMP, lyso-
somal cathepsins are released to the cytoplasm [43], as shown in Fig. 5D
and S6D. Likewise, α-tocopherol, a molecule reported to protect lyso-
somes against CADs based on their redistribution to non-lysosomal
membranes and the stabilization of the lysosome membrane itself
[44,45], strongly reverted the cytotoxicity induced by ANHAs (Fig. 5E
and S7A). In concordance with the increase of the lysosomal compart-
ment upon ANHA treatment, the autophagic flux augmented in the
presence of these drugs as measured by CytoID staining by flow cytom-
etry (Fig. 5F and S7B). Indeed, the amount of LC3-II, a canonical marker
for autophagic activity [46], was higher in cells treated with ANHAs,
both in AML cell lines (Fig. 5G) and primary AML patient samples
(Fig. S7C). However, the autophagy inhibitor 3-methyladenine (3-MA)
was unable to revert the antileukaemic effect of ANHAs (Fig. 5H and
S7D). Thus, ANHAs present lysosomotropism and induce autophagy, al-
though alternative cell death pathways might be involved.3.5. ANHAs damaged the mitochondrial compartment
Prior to lysosomes, CADsmay accumulate in themitochondrial com-
partment [47]. Also, LMP can activate the intrinsic apoptosis pathway
[48]; consequently, the mitochondrial status was investigated. Mito-
chondrial oxidative stress measured by the generation of reactive oxy-
gen species (ROS) was induced by ANHAs (Fig. 6A and S8A) and the
ROS scavenger N-acetylcysteine (NAC) cytoprotected AML cells in
their presence (Fig. 6B), in a ROS-dependentmanner (Fig. S8B). Themi-
tochondrial membrane potential (ΔΨm) was also severely dissipated
upon treatment (Fig. 6C and S8C), suggesting that ANHAs also affected
the mitochondrial functionality. Both ROS generation and loss of ΔΨm
leads to the activation of the apoptosis-associated executioner caspases
3 and 7. Consequently, caspases 3/7 were activated after ANHAFig. 1. A subgroup of antihistamines displays antileukaemic effects in AML cell lines. (A) Viab
histamine (H, yellow). HRH1 antagonists (blue): acrivastine (Ac), clemastine (Cl), cetirizine (
(Ru), terfenadine (Te), ebastine (Eb). HRH2 antagonists (dark green): ranitidine (Ra), cim
antagonists (green): JNJ7777120 (J0), JNJ10191584 (J4). Bars show mean ± SEM of triplicate
MM (green) and THP1 (blue) cells treated 48 h with ebastine or rupatadine. (C). CFSE prolifer
or terfenadine 10 μM. CFSE MFI at days 1, 3, 5 and 7. (D). Clonogenicity assays in AML cell line
CFUs counted at day 10. (E). Expression of monocytic (CD14) and granulocytic (CD11b) mar
72 h. Bars show mean ± SEM of triplicates (2 experiments). (F). Cell cycle analysis of KG1 cel
of cell cycle phases referred to control. Bars show mean ± SEM of triplicates (2 experimen
treated; green: G0/G1, yellow: S, blue: G2/M). (G) Viability of KG1 cells treated for 48 h with
(left) of bone marrow stroma (HS-5). Bars show mean ± SEM of triplicates (3 experiment
concentration. Bars show mean ± SEM of triplicates of representative experiment (3 experimetreatment (Fig. 6D and S8D); although the inhibition of caspases by z-
VAD-FMK had no significant effect on ANHA treatment induced cell
death (Fig. 6E and S8E-F), suggesting that several cell death programs
might be activated. Regardless, the canonical apoptosis marker
Annexin-V was upregulated in a dose-response manner (Fig. 6F and
S8G).
Due to the cross-talk between mitochondrial and lysosomal com-
partment during activation of the cell death program, the temporal in-
duction of mitochondrial and lysosomal damages was studied.
Mitochondrial ROS generation peaked 4 h post-treatment; while cas-
pase 3/7 activation, lysosomal enlargement and autophagosome accu-
mulation were induced 6–12 h after treatment (Fig. 6G). Although
ROS is a described LMP-inducer, the increase in lysosomal volume can-
not be also attributed, suggesting that ANHAs might be exerting their
antileukaemic effect simultaneously on both organelles and are both
relevant for cell death.
Lysosomo- and mitochondriotropism require passive membrane
diffusion and sequestration inside these organelles. Passive permeabil-
ity across lipid membranes is correlated positively with lipophilicity
and negativelywith polarity; thus, high logD (pH 7.4) and low TPSA (to-
pological polar surface area) predicts high passive diffusion across bio-
logical membranes [39]. Ion trapping is generally responsible for drug
accumulation in lysosomes and mitochondria, where protonation of
the amines present in CADs are driven by pH and/orΔΨ [47]. In concor-
dance with the dual effect on lysosomes and mitochondria, ANHAs had
high logD (Fig. 7A) and an intermediate-low TPSA value (Fig. 7B). In-
deed, ANHAs clustered when these two parameters were analysed,
showing a different profile as compared to non-ANHA antihistamines
(Fig. 7B); further confirming the relevance of physicochemical proper-
ties rather than specific molecular recognition parameters for their an-
tineoplastic potential (Fig. 7C).4. Discussion
Despite high complexity and heterogeneity, several alterations in
cell organelles are thought to be shared across AML patient cells as com-
pared to their healthy counterparts, including an enlarged lysosomal
size and frailty [40,49] and a plethora of mitochondrial changes, such
as an increased ROS content [50–53] and dysfunctional metabolism
[54], rendering AML cells more vulnerable to drugs targeting those cel-
lular compartments. In an in silico screening searching for small mole-
cules that might revert an early transformation signature in AML,
several antihistamines were identified as highly-effective and selective
antileukaemic agents by a dual mitochondrial-lysosomal targeting.
Indeed, this group of antihistamines (ANHAs)were effective against dif-
ferent types of lymphoblastic and myeloid neoplasias, highlighting the
potential clinical utility of mitochondrial-lysosomal disrupters for the
treatment of leukaemia.
As the transformation process leads, in general, to an increase in the
lysosome biogenesis andmass, an alteration in the sphingolipid metab-
olism, and an augmentation of ROS [55,56], these antihistamines acted
also against different types of leukaemia. Mitochondria can beility of KG-1 cells after 72 h-treatment with histamine-related ligands (10 μM). Agonist:
Ce), cyproheptadine (Cy), ketotifen (Ke), fexofenadine (Fe), loratadine (Lo), rupatadine
etidine (Ci), famotidine (Fa). HRH3 antagonists (light green): JNJ5207852 (J2). HRH4
s (2 experiments). (B) Cytotoxicity dose-response curves of HL60 (grey), KG1 (orange),
ation assay in KG1 cells treated with loratadine 10 μM, rupatadine 10 μM, ebastine 10 μM
s treated with loratadine 10 μM, rupatadine 10 μM, terfenadine 10 μM or ebastine 10 μM.
kers in KG1 cells treated with 10 μM loratadine, 10 μM rupatadine or 5 μM ebastine for
ls treated with loratadine 10 μM, rupatadine 10 μM, or ebastine 10 μM. Left: Frequencies
ts). Right: representative cytometric histograms (left: vehicle-treated, right: ebastine-
loratadine 10 μM, rupatadine 10 μM, or ebastine 5 μM in the presence (right) or absence
s). (H). 48 h-viability of KG-1 cells treated with ebastine and/or ara-C at the indicated
nts). *or# p b .05; **or## p b .01; *** p b .001; **** p b .0001 (t-tests).
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E5 45.3 3.7 12.2
E10 90.9 7.8 11.7
L20 37.8 20.6 1.8
R20 37.7 4.1 9.2
%CFU reduction
AML BC A/H
E5 63.1 3.9 16.2
E10 83.4 34.8 2.4
L20 33.8 8.0 4.2




































     Ø          Loratadine           Rupatadine              Ebastine           Terfenadine
AML patients
Cord Blood
Fig. 2. ANHAs selectively target AML cells ex vivo. (A) AML patient samples were treated with ANHAs loratadine (dark blue; 5, 10 and 20 μM), rupatadine (orange; 5, 10 and 20 μM),
ebastine (light blue; 1, 5 and 10 μM) or terfenadine (green; 1, 5 and 10 μM). Blast viability was assessed at day 3 and 6. Each symbol corresponds to an AML patient sample (n = 16),
and each point to a measure. (B). Clonogenicity assay (day 14) in AML patient samples treated with loratadine 10 and 20 μM (Lora), rupatadine 10 and 20 μM (Rupa), ebastine 5 and
10 μM (Ebas) or terfenadine 5 μM (Terfe). Each symbol corresponds to an AML represents a sample (n = 8), each point to a measure. (C). Viability of mononuclear cells from healthy-
donor buffy coats was assessed after 3- or 6-day treatment with loratadine 20 μM, rupatadine 20 μM, ebastine 10 μM or terfenadine 5 μM. Bars show mean ± SEM of 5 healthy
samples assayed in triplicates. (D). Lineage-depleted UCB cells were applied for 18 h the same treatment as in (C) and cultured as in (B). Left panel: total number of CFUs normalized
to control; right panel: frequency of colony subtypes. 3 different samples are represented in triplicates. Bars show mean ± SEM. (E). Ex vivo effects of ANHAs on healthy and AML
samples were compared in terms of viability (left), and clonogenicity (right). Data represent viability or clonogenicity reduction of treatments with ebastine 5 and 10 μM (Eb),
loratadine 20 μM (Lo) or rupatadine 20 μM (Ru). Bars show superimposed mean + SEM of data from Figs. 2A to 2D. Tables show mean percent reduction in viability or CFU formation,
as well as its fold of change (FC; effect on AML/ healthy samples). *p b .05; ** p b .01; *** p b .001; **** p b .0001 (Mann-Whitney tests).
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Fig. 3. ANHAs selectively target AML cells in vivo. (A).Conditioned NSG mice (n = 25) were intravenously transplanted with AML patient samples (AML#2, AML#3 and AML#14)
previously treated for 18 h with ebastine 10 μM (Ebas, light blue), rupatadine 10 μM (Rupa, orange) or loratadine 10 μM (Lora, dark blue). After 8 weeks, engraftment was analysed in
bone marrow (BM). Frequency of human AML blasts in BM is represented as mean value normalized to vehicle-treated control ± SEM. A representative flow plot from each
experimental mouse group is shown. (B). Conditioned NSG mice (n = 36) were intravenously transplanted with lineage-depleted cord blood samples (n = 3) previously treated for
18 h with ebastine 10 μM (Ebas, light blue) or rupatadine 10 μM (Rupa, orange). After 8 weeks, engraftment was analysed in bone marrow (BM). Frequency of human blood cells in
BM is represented as mean value normalized to vehicle-treated control ± SEM. A representative flow plot from each experimental mouse group is shown. (C). Engrafted cell
subpopulations from (B) were analysed according to CD34, CD13 and CD19 positivity to assess changes in the frequency of progenitors, myeloid and B cells respectively. Bars show
frequency of each population normalized to vehicle-treated control ± SEM. (D). In vivo effects of ANHAs on healthy and AML samples were compared in terms of engrafttment. Data
represent engraftment after treatment with ebastine 10 μM (Eb, light blue) or rupatadine 20 μM (Ru, orange). Bars show superimposed mean + SEM of data from Fig. 3A and B.
Tables show mean percent reduction of engraftment in AML and cord blood (CB) samples, as well as its fold of change (FC; effect on AML/effect on CB). *p b .05; ** p b .01; *** p b
.001; **** p b .0001 (t-tests).
228 J.M. Cornet-Masana et al. / EBioMedicine 47 (2019) 221–234successfully targeted at different levels in acute [57,58] and chronic leu-
kaemias [59]. Indeed, the more primitive leukaemic cell fraction is usu-
ally the most sensitive to mitochondria-targeted drugs [58–61].
Sensitivity to mitochondrial damage is thought to be a common prop-
erty not only of LSCs but also of other cancer stem cell populations
[62,63]. Similarly, different effective preclinical therapeutic approaches
have been described for lysosome destabilization in leukaemia
[40,64–66]. ANHAs damage mitochondria and lysosomes, targeting
two fragile organelles in cancer cells. Although an extensive crosstalk
between mitochondria and lysosomes is found in cancer cells [67],
dual simultaneous targeting may increase efficacy and specificity, con-
stituting a clinical opportunity for selective therapeutic approaches.
Due to the inter- and intrapatient heterogeneity and the darwinian na-
ture of leukaemia, combination therapies are likely to provide high
specificity in low concentration ranges, reducing toxicity and sideeffects. ANHAs showed an interesting collaborative effectwith currently
used cytarabine; thus, sensitizing leukaemic cells to conventional
therapy.
The role of antihistamines in cancer has been controversial mainly
due to the lack of consistency across different HRH1 inhibitors and
the absence of a defined role of its well-described HRH1 molecular tar-
get on cancer cells [15]. In haematological neoplasias, several antihista-
mines have been shown to affect leukaemia cell viability to different
extents [17,68–71]. All of them display CAD-associated properties
(high logD pH 7.4 and intermedium-low TPSA) compatible to the
model proposed. Interestingly, those antihistamines that presented no
antileukaemic effect could be predicted by our model [17,68,69,71]. As
most CADs, ANHAs are lysosomotropic drugs that induce irreversible
damage to lysosomes [40,41]. Recently, certain tropism tomitochondria









































































































































































































Fig. 4.ANHA's antileukemic effects are independent of HRH1. (A). Representative flow cytometry histograms of HRH1 surface expression on AML cell lines. Grey shadow, control; red line,
HL-60; blue line, KG-1; green line, MM. (B). Representative HRH1 surface staining (green) onHL-60 and KG-1 cells by immunofluorescence. Nuclei are stainedwith Hoechst33342 (blue).
(C). KG-1 cells were treated with ANHAs alone or in combination with histamine 200 μM. Viability was measured by flow cytometry (7AAD-, Hoechst+). Bars show mean ± SEM of
triplicates from a representative experiment (three independent experiments were performed). (D). 72 h cytotoxicity data from Fig. 1A (antihistamine-treated KG-1 cells) were
correlated with the corresponding pKi value for each drug. Left panel includes a regression line and its corresponding R2. Right panel shows pKis for ANHAs and non-ANHAs.
Horizontal lines represent means. (E). Frequency of HRH1 expression on the surface of cell lines from haematological neoplasias, either myeloid (yellow), T (green) or B (blue) lineage,
as detected by flow cytometry. (F). Cell lines from different haematological neoplasias were treated for 72 h with ebastine at 10 μM and viability was assessed by flow cytometry. Bars
show mean ± SEM of triplicates from 2 independent experiments. (G). 72 h cytotoxicity data from Fig. 4F (Ebastine 10 μM -treated KG-1 cells, Y axis) were correlated with the
corresponding %HRH1 expression of each cell line (X axis, data from Fig. 4E). Graphs include regression lines and their corresponding R2. Right panel shows pKis for ANHAs and non-
ANHAs. Error bars represent SEM. *p b .05; ** p b .01; *** p b .001; **** p b .0001 (t-tests).
229J.M. Cornet-Masana et al. / EBioMedicine 47 (2019) 221–234lysosome/mitochondria targeting is described for ANHA in leukaemic
cells, prompting the activation of the lysosome-mediated autophagy
and the intrinsic apoptosis, and probably multiplying the selectivity
windows given by tumoral alterations (Fig. 7), enabling the develop-
ment of highly effective therapies with reduced side effects.
Clinical data from the Danish Cancer Register revealed that well-
tolerated CAD antihistamines combined with the standard cancer che-
motherapy regimen improved survival of solid tumor patients. Remark-
ably, no clinical benefit was observed when non-CAD antihistamineswere assayed [72]. ANHAs have high apparent volumes of distribu-
tion [44,72], which facilitates an extensive distribution through all
the organs of the body because of their liposolubility and non-
ionization. However, low distribution volumes compatible with the
therapeutic objective are desirable to avoid side effects and increase
effectiveness. Additionally, ANHAs are quickly metabolized in the
body and metabolites are not predicted to be active against leukae-
mia according to the proposed model. Thus, the clinical use of
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Fig. 5. ANHAs induce an expansion in lysosomal and autophagic compartments. (A). Confocal microscopy images of KG-1 cells treated 18 h with control or ebastine 5 μM, stained with
LysoTracker DeepRed 50 nM and Hoechst33342. Left: 630× (scale = 25 μm); right: 1260× (scale = 5 μm). (B). KG-1 cells treated 24 h with control (Ø) ebastine 5 μM (Eb),
rupatadine10μM (Ru), loratadine10μM (Lo) or chloroquine20μM (Ch), stained with LysoTracker 50 nM and analysed by cytometry. Bars represent mean ± SEM of triplicates (2
experiments). (C). KG-1 cells were treated 18 h with control or ebastine 5/7.5 μM; galectin-1 (LGALS1, green) distribution was assessed by immunofluorescence. Representative
images shown (1260×; scale = 5 μm). Right: frequency of cells with galectin-1 puncta (mean ± SEM, 2 experiments). (D). KG-1 cells were treated 18 h with vehicle control or
ebastine 7.5 μM, and cathepsinB (CTSB, green) distribution was assessed by immunofluorescence. Representative images shown (1260×; scale = 5 μm). (E). Viability of KG-1 after 1
h-treatment with α-tocopherol (500, 1000 and 2000 μM) followed by 48 h-treatment with ebastine 10 μM (Ebas), loratadine 10 μM (Lora), or rupatadine 10 μM (Rupa). Bars
represent mean ± SEM of triplicates from representative experiment (2 experiments). (F). KG-1 cells treated 48 h with control (Ø) ebastine 5 μM (Eb), rupatadine 10 μM (Ru),
loratadine 10 μM (Lo) or chloroquine 20 μM (Ch), stained with CYTO-ID and analysed by flow cytometry. Bars represent mean ± SEM of triplicates (2 experiments). (G). HL-60, KG-1,
MonoMac-1 and THP-1 cells were treated 24 h with control (Ø) ebastine 10 μM (Eb), rupatadine 10 μM (Ru), loratadine 10 μM (Lo) or chloroquine 20 μM (Ch). Proteins were
extracted and run in a western blot using LC3 and GAPDH antibodies. Representative membranes shown. Data in dot plot; each symbol corresponds to a cell line, each point to a
replicate. (H). Viability of KG-1 cells after 48 h-treatment with control (Cont), 3-MA 500 μM, ebastine 7 μM (Ebas) or a combination of both (Combo). Bars show mean ± SEM of
triplicates from a representative experiment (2 experiments). *p b .05; ** p b .01; *** p b .001; **** p b .0001 (t-tests).
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Fig. 6. ANHA-induced cell death partly depends on mitochondrial homeostasis disruption. (A). MitoSOX Red superoxide indicator staining in KG-1 cells were treated 6 h with vehicle
control (Ø) ebastine 10 μM (Eb), rupatadine 10 μM (Ru), loratadine 10 μM (Lo) or rotenone 0,1 μM (Ro). Bars show mean ± SEM of triplicates from two independent experiments.
(B). THP-1 cells were treated for 48with increasing concentrations of N-acetyl cysteine (NAC; 2, 5 and 10mM) and ebastine 5 or 10 μM (Ebas). Cell viability was assessed by flow cytom-
etry. Bars represent mean ± SEM of triplicates from a representative experiment (3 independent experiments). (C). KG-1 cells were treated for 18 h with ebastine 7.5 μM (Eb5, Eb10),
loratadine 10 μM (Lora) or rupatadine 10 μM (Rupa). After 18 h, cells were stained with rhodamine 123 and analysed by flow cytometry. Bars show mean ± SEM of triplicates from
two independent experiments (D). KG-1 cells were treated for 6 or 24 h with vehicle control (grey), loratadine 10 μM (dark blue), rupatadine 10 μM (orange), ebastine 10 μM (light
blue) or etoposide 5 μM (red). Caspase activation was analysed using Caspase-Glo ® 3/7 assay. Bars show mean ± SEM of triplicates from two independent experiments (E). KG-1
cells were treated with ebastine 5 or 10 μM (Eb), loratadine 10 μM (Lora) or rupatadine 10 μM (Rupa) in the presence or absence of Z-VAD-FMK 50 μM, and viability was assessed
after 48 h. Bars showmean ± SEM of triplicates from a representative experiment (out of 3 independent experiments) (F). KG-1 cells were treated with ebastine 1, 5 or 10 μM and fre-
quency of annexin V+ cells was assessed by flow cytometry at 48 h. Bars showmean± SEM of triplicates from a representative experiment (3 independent experiments) *p b .05; ** p b
.01; *** p b .001; **** p b .0001 (t-tests).
231J.M. Cornet-Masana et al. / EBioMedicine 47 (2019) 221–234improve biodistribution and pharmacokinetics (including metabolism
protection). Recently, a new formulation of two commonly used che-
motherapeutics has been approved for AML. CPX-351 (Vyxeos, Jazz
Pharmaceuticals) is a new liposomal formulation that encapsulates
cytarabine and daunorubicin in a fix molar rate. Cytarabine and dau-
norubicin are rapidly metabolized after administration and become
undetectable within the first hour. However, CPX-351-encapsulated
cytarabine and daunorubicin administration produce sustained
plasma levels of both drugs for several hours, protecting both
drugs from metabolism and elimination. Moreover, leukaemic cells
exhibit preferential uptake of CPX-351 liposomes when compared
with healthy cells [73–75]. Therefore, future clinical development of
a liposome-based encapsulated form of ANHA drugs might overcomethe high metabolism rate, permitting a sustained presence of non-
catabolized ANHA drugs able to widely reach leukaemic cells.
Here, a groupof physicochemical properties present in someantihis-
tamines has been defined for specifically passive targeting of leukaemic
cells, particularly themost primitive cellular subpopulation of LSCs. The
antineoplastic effect is mediated by the concurrent disruption of lyso-
somal and mitochondrial homeostasis in cancer cells, which are more
sensitive than their healthy counterparts. This therapeutic strategy
seems to be highly specific andwidely safe. However, drug delivery op-
timization is needed for achievement of the therapeutic dose at the can-
cer cell localization. Targeting the mitochondrial and lysosomal
compartment in leukaemic cells holds great promises in the fight
against leukaemia as it provides an alternative pathway to currently
Fig. 7. ANHAs simultaneously target mitochondria and lysosomes (A).KG-1 cells were treated with ebastine 10 μM, loratadine 10 μM or rupatadine 10 μM and different parameters were
analysed at the indicated times; caspase activation (caspaseGLO), autophagy (CYTO-ID), lysosomal volume (LysoTracker) and mitochondrial ROS (MitoSOX). Each point represents the
mean of triplicates from two independent experiments. (B). Calculated logD7,4 values obtained from ChEMBL (ACDLabs calculations) were plotted for each functional antihistamine
group. Each point represents an antihistamine (C). Antihistamines were plotted according to their calculated logD7,4 and their calculated topological polar surface area (TPSA,
drugbank.ca). ANHAs are represented in green, non-ANHAs in red, and intermediate antihistamines in yellow. (D). Model depicting the hypothesized antileukaemic mechanism of
action of antihistamines.
232 J.M. Cornet-Masana et al. / EBioMedicine 47 (2019) 221–234used chemotherapy that engages alternative cell death programs to
which leukaemic cells are sensitive.
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